ANG Lifesciences India Limited is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 354 | 220 | 146 | 93 | 93 |
| EBITDA (ex other income) | 67 | 14 | 8 | (2) | 1 |
| margin % | 19.0 | 6.4 | 5.4 | (2.4) | 0.8 |
| Owners' profit | 0 | 0 | 0 | 0 | 0 |
| EPS, as reported (₹) | 39.09 | 0.36 | (7.61) | 9.42 | 8.43 |
| ROE % · ROCE % | 48.1 · 50.0 | (0.3) · 12.4 | (13.3) · 0.2 | (19.4) · (8.1) | (21.0) · (8.5) |
| Debt / equity (x) | 0.92 | 0.81 | 0.91 | 1.26 | 1.47 |
| Cash from operations | 25 | 26 | (9) | (0) | 11 |
| Capex | (41) | (10) | (6) | (4) | (0) |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 18 | 33 | 25 | 17 | 25 | 26 | 19 | 24 |
| Profit before tax | (4) | (1) | (6) | (4) | (3) | (3) | (6) | (1) |
| Net profit | (3) | (2) | (5) | (2) | (2) | (3) | (5) | (1) |
| EPS (₹) | (2.35) | (1.53) | (3.98) | 1.56 | 1.52 | 2.24 | 3.60 | 1.07 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Pharmaceutical | 49 | 50.6 |
| Printing & Publishers | 3 | 3.0 |
| Pharmaceuticals | 43 | 44.4 |
| Printing & Packaging | 2 | 2.1 |
| Total, before eliminations | 96 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 7 Sept 2026 · ANG Lifesciences submits Annual Report for FY 2025-26; 20th AGM on Sept 30 | results | medium | — | — |
| 7 Sept 2026 · ANG Lifesciences 20th AGM Notice - September 30, 2026 via VC | board shareholder meetings | low | — | — |
| 7 Sept 2026 · Book Closure for 20th AGM from 24 Sep to 30 Sep 2026 | board shareholder meetings | low | — | — |
| 7 Sept 2026 · 20th AGM scheduled for 30 September 2026 via video conference | board shareholder meetings | low | — | — |
| 7 Sept 2026 · ANG Lifesciences board fixes AGM date, re-appoints independent director | management changes | low | — | — |
| 7 Aug 2026 · Board meeting on 14 Aug 2026 to approve Q1 FY27 results | results | low | — | — |
| 21 Jul 2026 · Reg 74(5) compliance certificate filed for Q1 FY27 | compliance | minimal | — | — |
| 19 Jun 2026 · Trading Window Closure Ahead of Q1 FY27 Results | compliance | minimal | — | — |
| 5 Jun 2026 · Newspaper Publication of Audited Financial Results for the quarter and year ended March 31, 2026. | compliance | minimal | — | — |
| 30 May 2026 · Audited Results 31.03.2026 | results | high | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| 23.7 |
| 13.7 |
| 17.5 |
| 11.8 |
| 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 4.3 | 28.9 | 7 of 169 | 95% |
| P/B | 0.9 | 3.3 | 17 of 163 | 90% |
| ROCE | (21.7) | 10.8 | 171 of 183 | 7% |
| ROE | (21.0) | 10.4 | 164 of 171 | 4% |
| Debt / Equity | 1.5 | 0.1 | 164 of 171 | 4% |
| EBITDA margin | 12.1 | 17.5 | 107 of 165 | 35% |
| Revenue growth | 39.7 | 16.3 | 27 of 161 | 84% |
| Profit growth | 32.9 | 30.9 | 77 of 158 | 52% |
| Market cap | 47 | 839 | 151 of 182 | 17% |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
